Prelude Therapeutics Inc PRLD
$6.63 $0.13 (2.00%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
PRLD Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Prelude Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Prelude Therapeutics Inc. Stock Analysis PRLD
United States Health Care Small Cap Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 79 full-time employees. The company went IPO on 2020-09-25. By focusing on developing molecules using broad mechanisms that have multiple links to oncogenic driver pathways in select patients, it has developed a diverse pipeline consisting of multiple distinct programs, including kinases, targeted protein degraders, and degrader antibody conjugates. PRT12396 its lead, mutant-selective JAK2V617F inhibitor, is an open-label and multi-center study in patients with high-risk polycythemia vera and intermediate and high-risk myelofibrosis. JAK2V617F is the primary driver mutation responsible for disease progression in the majority of patients living with myeloproliferative neoplasms. The firm has discovered and is developing a series of selective and orally bioavailable KAT6A selective degraders. KAT6A is engaged in treating advanced breast cancer & other solid tumors.
Prelude Therapeutics Inc (PRLD) Chart
Financial Metrics & Statements of Prelude Therapeutics Inc (PRLD)
FAQ's for Prelude Therapeutics Inc (PRLD)
- As of August 2026, Prelude Therapeutics Inc PRLD is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Prelude Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Prelude Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Prelude Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Prelude Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Prelude Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Prelude Therapeutics Inc (PRLD)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
